AuthorisedHuman Pharmacology (Phase I)- OtherInterventional

Phase 1b study to assess the safety and tolerability of SR-878 in patients with rheumatoid arthritis

This is an early-stage study looking at a new potential medicine called SR-878 for people who have rheumatoid arthritis. The main aim is to carefully check if the medicine is safe to use and how well people tolerate it. This means researchers will be looking for any side effects and how comfortable participants are taking the medicine. Because it's an early study, it's not designed to see how effective the medicine is at treating rheumatoid arthritis yet. It's an important first step to see if SR-878 could be a future treatment option. The study is open to adults aged 18 and over, of any gender.

At a glance

Status

Authorised

Phase

Human Pharmacology (Phase I)- Other

Sponsor

SciRhom GmbH

Enrolment target

Start

24 Apr 2026

rheumatoid arthritis

What is this study about?

This study is focusing on a new medicine, or 'intervention', called SR-878, for people living with rheumatoid arthritis. Rheumatoid arthritis is a long-term condition that causes pain, swelling, and stiffness in the joints. This particular study is in a very early stage, often called 'Phase 1b'. This means it's one of the first times this medicine is being tested in people.

The main goal of this early study is not to cure rheumatoid arthritis or to see if SR-878 is better than existing treatments. Instead, the primary aim is to understand the safety of SR-878 and how well people can tolerate taking it. Researchers will be carefully monitoring participants for any unexpected effects or discomfort that might arise from the medicine.

Think of it as a foundational step. Before a new medicine can be widely used, doctors need to be sure it's safe for people to take. This study will gather crucial information about SR-878's safety profile, which will help guide future research into whether it could become an effective treatment option for rheumatoid arthritis down the line.

Key takeaways

This is an early study of a new medicine for rheumatoid arthritis.
The main aim is to check the medicine's safety and how well people tolerate it.
It's open to adults aged 18 and over, of any gender.
Taking part helps medical research, but the benefits for you are not yet known.
You can withdraw from the study at any time.

Who may be eligible?

To be considered for this study, you must be 18 years old or older. The study is open to both men and women.

Since this is a very early study, there will likely be other specific health requirements or conditions that you need to meet. For example, you might need to have a confirmed diagnosis of rheumatoid arthritis, and your doctors may need to check your general health to make sure it's safe for you to take part.

It's important to discuss your full medical history with the study team. They will review all your health information to see if this study is suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a diagnosis of rheumatoid arthritis?
Are you able to attend regular clinic visits?
Are you willing to take a new, experimental medicine?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would be taking the new medicine, SR-878, as directed by the study team. You would have several visits to the clinic where doctors and nurses would perform various assessments. These might include physical examinations, blood tests, and scans to monitor your health and how your body is reacting to the medicine. The team will be carefully looking for any side effects and making sure you are comfortable. There would also likely be follow-up visits or calls after you finish taking the medicine to continue monitoring your health. The total duration of your involvement in the study would be explained to you in detail by the study team.

Potential risks and benefits

Because SR-878 is a new medicine, its potential benefits for treating rheumatoid arthritis are not yet known, as this study primarily focuses on safety. However, taking part in a study like this helps advance medical knowledge and could potentially contribute to finding new treatments for rheumatoid arthritis in the future. As with any new medicine, there are potential risks, including side effects that are not yet fully understood. The study team will explain all known risks to you. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Romania

Common questions

What is rheumatoid arthritis?

Rheumatoid arthritis is a condition where your body's immune system attacks your own tissues, mainly causing pain, swelling, and stiffness in your joints.

What does 'Phase 1b' mean?

Phase 1b means this is one of the very first studies in people, mainly focused on checking if the new medicine is safe and well-tolerated, rather than how well it treats the condition.

Will this medicine cure my rheumatoid arthritis?

This early study is mainly focused on safety and is not designed to cure rheumatoid arthritis or assess its effectiveness yet.

Can I stop taking part in the study if I change my mind?

Yes, you can choose to leave the study at any time, for any reason, without it affecting your regular medical care.

What is SR-878?

SR-878 is a new, experimental medicine being tested for rheumatoid arthritis. Its full effects are still being investigated.